Rivastigmine intranasal - Lachesis Biosciences
Alternative Names: Rivastigmine nasal spray - Lachesis BiosciencesLatest Information Update: 29 Jul 2024
At a glance
- Originator Lachesis Biosciences
- Class Antidementias; Phenylcarbamates; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors; Butyrylcholinesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Alzheimer's disease
- Clinical Phase Unknown Dementia
Most Recent Events
- 29 Jul 2024 Rivastigmine is still in phase I trials for Alzheimer's disease in Australia (Lachesis Bioscineces website, July 2024)
- 29 Jul 2024 Rivastigmine is still in clinical trials for Dementia in Australia (Lachesis Bioscineces website, July 2024)
- 28 Jan 2023 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in Australia (Intranasal, Spray)